Analyzing immune cells in lung tumors
Biological Observational Monocentric Study Aimed at Analyzing the Lymphocytic Infiltrate of Lung Tumors
Scientific Institute San Raffaele · NCT06470607
This study is trying to understand how immune cells behave in lung tumors by collecting samples from patients with non-small cell lung cancer who are having surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Scientific Institute San Raffaele (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milan) |
| Trial ID | NCT06470607 on ClinicalTrials.gov |
What this trial studies
This observational study aims to reconstruct the molecular organization of thoracic tumors, particularly non-small cell lung cancer (NSCLC). It involves collecting clinical data and biological samples, including blood and tumor tissue, from 70 patients diagnosed with thoracic tumors who are candidates for surgical treatment. The study will take place during a single hospital visit, coinciding with the surgical procedure, and will last for a total of three years. The data collected will help in understanding the immune response in lung cancer.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 years old who are diagnosed with thoracic tumors and are eligible for surgical treatment.
Not a fit: Patients who have undergone chemotherapy in the last 6 months, are pregnant or breastfeeding, or have an immunosuppressive condition may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance our understanding of the immune landscape in lung tumors, potentially leading to improved treatment strategies.
How similar studies have performed: Other studies focusing on the immune response in cancer have shown promising results, indicating that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to provide informed consent; * Men and women over the age of 18; * Patients candidates for surgical treatment diagnosed with thoracic tumors Exclusion Criteria: * Previous chemotherapy for any cancer within the last 6 months; * Pregnant and/or breastfeeding women; * Immunosuppressive state (states of immunosuppression or ongoing immunosuppressive/immunomodulatory treatments)
Where this trial is running
Milan
- Scientific Institute Ospedale San Raffaele — Milan, Italy (RECRUITING)
Study contacts
- Study coordinator: Pierluigi Novellis, MD
- Email: novellis.pierluigi@hsr.it
- Phone: +39022643
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Cancer, Immune System, thoracic tumors, Immune checkpoints, lymphocytes